0	11	USF-related	usf-related	JJ
12	25	transcription	transcription	NN
26	32	factor	factor	NN
32	33	,	,	,
34	41	HIV-TF1	HIV-TF1	NNP
41	42	,	,	,
43	53	stimulates	stimulate	VBZ
54	67	transcription	transcription	NN
68	70	of	of	IN
71	76	human	human	JJ
77	93	immunodeficiency	immunodeficiency	NN
94	101	virus-1	virus-1	NN
101	102	.	.	.

104	107	The	the	DT
108	121	transcription	transcription	NN
122	128	factor	factor	NN
129	136	HIV-TF1	hiv-tf1	NN
136	137	,	,	,
138	143	which	which	WDT
144	149	binds	bind	VBZ
150	152	to	to	TO
153	154	a	a	DT
155	161	region	region	NN
162	167	about	about	IN
168	170	60	60	CD
171	173	bp	bp	NN
174	182	upstream	upstream	RB
183	187	from	from	IN
188	191	the	the	DT
192	200	enhancer	enhancer	NN
201	203	of	of	IN
204	207	the	the	DT
208	213	human	human	JJ
214	230	immunodeficiency	immunodeficiency	NN
231	238	virus-1	virus-1	NN
239	240	(	(	(
240	245	HIV-1	HIV-1	NNP
245	246	)	)	)
246	247	,	,	,
248	251	was	be	VBD
252	260	purified	purify	VBN
261	265	from	from	IN
266	271	human	human	JJ
272	273	B	B	NNP
274	279	cells	cell	NNS
279	280	.	.	.

281	288	HIV-TF1	HIV-TF1	NNP
289	292	had	have	VBD
293	294	a	a	DT
295	304	molecular	molecular	JJ
305	311	weight	weight	NN
312	314	of	of	IN
315	321	39,000	39,000	CD
321	322	.	.	.

323	330	Binding	binding	NN
331	333	of	of	IN
334	341	HIV-TF1	hiv-tf1	NN
342	344	to	to	TO
345	348	the	the	DT
349	352	HIV	HIV	NNP
353	357	long	long	JJ
358	366	terminal	terminal	JJ
367	373	repeat	repeat	NN
374	375	(	(	(
375	378	LTR	LTR	NNP
378	379	)	)	)
380	389	activated	activate	VBD
390	403	transcription	transcription	NN
404	408	from	from	IN
409	412	the	the	DT
413	416	HIV	HIV	NNP
417	425	promoter	promoter	NN
426	428	in	in	FW
429	434	vitro	vitro	FW
434	435	.	.	.

436	439	The	the	DT
440	455	HIV-TF1-binding	hiv-tf1-binding	JJ
456	460	site	site	NN
461	463	in	in	IN
464	467	HIV	HIV	NNP
468	471	LTR	LTR	NNP
472	475	was	be	VBD
476	483	similar	similar	JJ
484	486	to	to	TO
487	490	the	the	DT
491	495	site	site	NN
496	506	recognized	recognize	VBN
507	509	by	by	IN
510	518	upstream	upstream	JJ
519	530	stimulatory	stimulatory	JJ
531	537	factor	factor	NN
538	539	(	(	(
539	542	USF	USF	NNP
542	543	)	)	)
544	546	in	in	IN
547	550	the	the	DT
551	561	adenovirus	adenovirus	NN
562	567	major	major	JJ
568	572	late	late	JJ
573	581	promoter	promoter	NN
581	582	.	.	.

583	594	DNA-binding	dna-binding	JJ
595	605	properties	property	NNS
606	608	of	of	IN
609	616	HIV-TF1	HIV-TF1	NNP
617	626	suggested	suggest	VBD
627	631	that	that	IN
632	639	HIV-TF1	hiv-tf1	NN
640	645	might	might	MD
646	648	be	be	VB
649	658	identical	identical	JJ
659	661	or	or	CC
662	669	related	related	JJ
670	672	to	to	TO
673	676	USF	USF	NNP
676	677	.	.	.

678	691	Interestingly	interestingly	RB
691	692	,	,	,
693	702	treatment	treatment	NN
703	705	of	of	IN
706	714	purified	purify	VBN
715	722	HIV-TF1	hiv-tf1	NN
723	725	by	by	IN
726	737	phosphatase	phosphatase	NN
738	745	greatly	greatly	RB
746	753	reduced	reduce	VBD
754	757	its	its	PRP$
758	769	DNA-binding	dna-binding	JJ
770	778	activity	activity	NN
778	779	,	,	,
780	790	suggesting	suggest	VBG
791	795	that	that	IN
796	811	phosphorylation	phosphorylation	NN
812	814	of	of	IN
815	822	HIV-TF1	HIV-TF1	NNP
823	826	was	be	VBD
827	836	essential	essential	JJ
837	840	for	for	IN
841	844	DNA	DNA	NNP
845	852	binding	binding	NN
852	853	.	.	.

854	857	The	the	DT
858	868	disruption	disruption	NN
869	871	of	of	IN
872	887	HIV-TF1-binding	hiv-tf1-binding	JJ
888	892	site	site	NN
893	900	induced	induce	VBD
901	902	a	a	DT
903	905	60	60	CD
905	906	%	%	NN
907	915	decrease	decrease	NN
916	918	in	in	IN
919	922	the	the	DT
923	928	level	level	NN
929	931	of	of	IN
932	945	transcription	transcription	NN
946	950	from	from	IN
951	954	the	the	DT
955	958	HIV	HIV	NNP
959	967	promoter	promoter	NN
968	970	in	in	FW
971	975	vivo	vivo	FW
975	976	.	.	.

977	982	These	these	DT
983	990	results	result	NNS
991	998	suggest	suggest	VBP
999	1003	that	that	IN
1004	1011	HIV-TF1	hiv-tf1	NN
1012	1014	is	be	VBZ
1015	1023	involved	involve	VBN
1024	1026	in	in	IN
1027	1042	transcriptional	transcriptional	JJ
1043	1053	regulation	regulation	NN
1054	1056	of	of	IN
1057	1062	HIV-1	HIV-1	NNP
1062	1063	.	.	.